File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study

TitleA multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study
Authors
KeywordsMedical sciences
Oncology medical sciences
Radiology and nuclear medicine pharmacy and pharmacology biology
Cytology and histology
Issue Date2013
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
The 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 31 May-4 June 2013. In Journal of Clinical Oncology, 2013, v. 31 n. 15 suppl., abstract no. 4117 How to Cite?
AbstractBACKGROUND: This is a single arm, multi-center, phase II study to assess the efficacy and tolerability of sorafenib, oxaliplatin and capecitabine combination for the treatment of advanced hepatocellular carcinoma (HCC) pat...
DescriptionGeneral Poster Session - Gastrointestinal (Noncolorectal) Cancer: abstract no. 4117
Open Access Journal
Persistent Identifierhttp://hdl.handle.net/10722/186808
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorYau, TCCen_US
dc.contributor.authorCheung, FYen_US
dc.contributor.authorLee, Fen_US
dc.contributor.authorChoo, SPen_US
dc.contributor.authorWong, HYHen_US
dc.contributor.authorToh, HCen_US
dc.contributor.authorLeung, AKen_US
dc.contributor.authorChan, Pen_US
dc.contributor.authorYau, TKen_US
dc.contributor.authorWong, Jen_US
dc.contributor.authorTang, YFen_US
dc.contributor.authorLau, JSMen_US
dc.contributor.authorCheung, TTen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorPoon, RTPen_US
dc.date.accessioned2013-08-20T12:21:07Z-
dc.date.available2013-08-20T12:21:07Z-
dc.date.issued2013en_US
dc.identifier.citationThe 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 31 May-4 June 2013. In Journal of Clinical Oncology, 2013, v. 31 n. 15 suppl., abstract no. 4117en_US
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/186808-
dc.descriptionGeneral Poster Session - Gastrointestinal (Noncolorectal) Cancer: abstract no. 4117-
dc.descriptionOpen Access Journal-
dc.description.abstractBACKGROUND: This is a single arm, multi-center, phase II study to assess the efficacy and tolerability of sorafenib, oxaliplatin and capecitabine combination for the treatment of advanced hepatocellular carcinoma (HCC) pat...-
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectRadiology and nuclear medicine pharmacy and pharmacology biology-
dc.subjectCytology and histology-
dc.titleA multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group studyen_US
dc.typeConference_Paperen_US
dc.identifier.emailYau, TCC: tyaucc@hku.hken_US
dc.identifier.emailWong, HYH: h9904815@graduate.com.hken_US
dc.identifier.emailTang, YF: vyftang@hku.hken_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.authorityYau, TCC=rp01466en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros217135en_US
dc.identifier.volume31-
dc.identifier.issue15 suppl.-
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 131016-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats